Magnesium

Summary

Magnesium (CHEMBL1201230) is an approved small molecule targeting HCN1, HCN2, and KCNJ1; indicated across 5 conditions including stomatitis and drug-induced liver injury.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 21 (HCN1, HCN2, KCNJ1…)
• Indications: 5 conditions
• Clinical trials: 194
• Chemistry: 24.305 Da · Mg

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201230
Name	Magnesium
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	5462224
ChEBI	CHEBI:25107
Molecular formula	Mg
Molecular weight	24.305
InChIKey	FYYHWMGAXLPEAU-UHFFFAOYSA-N

SMILES: [Mg]

IUPAC name: magnesium

Pharmacological roles (ChEBI): macronutrient.

Also known as: Magnesium, magnesium, MAGNESIUM

Patent coverage: 1,098 distinct patent families (1,354 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	5-HT3A	Negative
HCN1	HCN1		3.3	0%	O60741
HCN2	HCN2		3.2	4.2%	Q9UL51
KCNJ1	Kir1.1		2.2	0%	P48048
KCNJ2	Kir2.1	Antagonist	4.8	0%	P63252
KCNJ12	Kir2.2		4.96	0%	Q14500
KCNJ4	Kir2.3	Antagonist	5	4.4%	P48050
KCNJ14	Kir2.4			0.9%	Q9UNX9
GRIN2A	GluN2A			0.4%	Q12879
GRIN2B	GluN2B			0%	Q13224
GRIN2C	GluN2C			0.2%	Q14957
GRIN2D	GluN2D			0.2%	O15399
TRPC5	TRPC5	Inhibition	3.34	0%	Q9UL62
TRPM3	TRPM3	Antagonist	2	0.1%	Q9HCF6
TRPM6	TRPM6			0.1%	Q9BX84
TRPM7	TRPM7	Antagonist	2.49	62.2%	Q96QT4
TRPV5	TRPV5			0%	Q9NQA5
TRPV6	TRPV6			0.3%	Q9H1D0
CASR	CaS receptor	Partial agonist	2.4	0.1%	P41180
	VRAC
RYR1	RyR1	Antagonist		1%	P21817
RYR2	RyR2	Antagonist		0.3%	Q92736
RYR3	RyR3	Antagonist		0%	Q15413

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 21 target gene(s): HCN1, HCN2, KCNJ1, KCNJ2, KCNJ12, KCNJ4, KCNJ14, GRIN2A, GRIN2B, GRIN2C, GRIN2D, TRPC5, TRPM3, TRPM6, TRPM7, TRPV5, TRPV6, CASR, RYR1, RYR2, RYR3.

Top Reactome pathways

44 total, by targets touching each:

Pathway	Targets	Genes
Muscle contraction	7	KCNJ12, KCNJ14, KCNJ2, KCNJ4, RYR1, RYR2, RYR3
Cardiac conduction	7	KCNJ12, KCNJ14, KCNJ2, KCNJ4, RYR1, RYR2, RYR3
TRP channels	6	TRPC5, TRPM3, TRPM6, TRPM7, TRPV5, TRPV6
Neuronal System	5	KCNJ1, KCNJ12, KCNJ14, KCNJ2, KCNJ4
Inwardly rectifying K+ channels	5	KCNJ1, KCNJ12, KCNJ14, KCNJ2, KCNJ4
Potassium Channels	5	KCNJ1, KCNJ12, KCNJ14, KCNJ2, KCNJ4
Classical Kir channels	4	KCNJ12, KCNJ14, KCNJ2, KCNJ4
Unblocking of NMDA receptors, glutamate binding and activation	4	GRIN2A, GRIN2B, GRIN2C, GRIN2D
Phase 4 - resting membrane potential	4	KCNJ12, KCNJ14, KCNJ2, KCNJ4
Neurexins and neuroligins	4	GRIN2A, GRIN2B, GRIN2C, GRIN2D
Synaptic adhesion-like molecules	4	GRIN2A, GRIN2B, GRIN2C, GRIN2D
Assembly and cell surface presentation of NMDA receptors	4	GRIN2A, GRIN2B, GRIN2C, GRIN2D
Negative regulation of NMDA receptor-mediated neuronal transmission	4	GRIN2A, GRIN2B, GRIN2C, GRIN2D
Long-term potentiation	4	GRIN2A, GRIN2B, GRIN2C, GRIN2D
Neurotransmitter receptors and postsynaptic signal transmission	3	KCNJ12, KCNJ2, KCNJ4
Transmission across Chemical Synapses	3	KCNJ12, KCNJ2, KCNJ4
Activation of G protein gated Potassium channels	3	KCNJ12, KCNJ2, KCNJ4
G protein gated Potassium channels	3	KCNJ12, KCNJ2, KCNJ4
Stimuli-sensing channels	3	RYR1, RYR2, RYR3
Transport of small molecules	3	RYR1, RYR2, RYR3
Ion homeostasis	3	RYR1, RYR2, RYR3
GABA receptor activation	3	KCNJ12, KCNJ2, KCNJ4
GABA B receptor activation	3	KCNJ12, KCNJ2, KCNJ4
Ion channel transport	3	RYR1, RYR2, RYR3
Activation of GABAB receptors	3	KCNJ12, KCNJ2, KCNJ4
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits	3	KCNJ12, KCNJ2, KCNJ4
HCN channels	2	HCN1, HCN2
Ras activation upon Ca2+ influx through NMDA receptor	2	GRIN2B, GRIN2D
RAF/MAP kinase cascade	2	GRIN2B, GRIN2D
MECP2 regulates neuronal receptors and channels	2	GRIN2A, GRIN2B
Potassium transport channels	1	KCNJ1
Signal Transduction	1	CASR
Signaling by GPCR	1	CASR
GPCR downstream signalling	1	CASR
EPHB-mediated forward signaling	1	GRIN2B
G alpha (q) signalling events	1	CASR
G alpha (i) signalling events	1	CASR
Role of second messengers in netrin-1 signaling	1	TRPC5
Class C/3 (Metabotropic glutamate/pheromone receptors)	1	CASR
GPCR ligand binding	1	CASR
Activated NTRK2 signals through FYN	1	GRIN2B
Sensory Perception	1	KCNJ2
Sensory perception of taste	1	KCNJ2
Sensory perception of sour taste	1	KCNJ2

Dominant GO biological processes

GO term	Targets
monoatomic ion transport	20
monoatomic ion transmembrane transport	20
transmembrane transport	11
calcium ion transmembrane transport	10
calcium ion transport	10
protein homotetramerization	8
potassium ion import across plasma membrane	7
potassium ion transport	7
monoatomic cation transmembrane transport	7
calcium ion transmembrane import into cytosol	6
calcium-mediated signaling	6
regulation of membrane potential	5
regulation of monoatomic ion transmembrane transport	5
brain development	4
ionotropic glutamate receptor signaling pathway	4

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
stomatitis	2	MONDO:0004842	EFO:0009688
drug-induced liver injury	2	MONDO:0005359	EFO:1000905
sickle cell disease	2	MONDO:0011382	MONDO:0011382

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 194.

Phase distribution

Phase	Trials
Not specified	92
PHASE4	36
PHASE3	26
PHASE2	16
PHASE1/PHASE2	8
PHASE1	8
PHASE2/PHASE3	5
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04166877	PHASE4	RECRUITING	Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
NCT05488847	PHASE4	ACTIVE_NOT_RECRUITING	Opioid-Free Pain Protocol After Shoulder Arthroplasty
NCT06442995	PHASE4	RECRUITING	Evaluation of the Efficacy of the Addition of Magnesium Sulfate to Morphine on the Occurrence of Acute Urinary Retention Following Epidural Anesthesia for Cesarean Section.
NCT06677827	PHASE4	NOT_YET_RECRUITING	Effect of Adding Magnesium Sulphate as Adjuvant to Bupivacaine in Ultrasound Guided External Oblique Intercostal Plane Block in Upper Abdominal Cancer Surgery.to Assess the Total Postoperative Opioid Consumption in the First 24 h and Evaluate Post Operative VAS Score
NCT06685705	PHASE4	NOT_YET_RECRUITING	Comparative Study Between Intrathecal Magnesium Sulfate, Neostigmine and Fentanyl as Adjuvant for Bubivacaine in Postoperative Analgesia in Lower Abdominal Surgeries
NCT06902285	PHASE4	RECRUITING	Magnesium-L-Threonate for Sleep Quality Post-Arthroplasty
NCT06966102	PHASE4	NOT_YET_RECRUITING	Lidocaine Infusion Versus Magnesium Infusion in Decreasing Fentanyl Requirements in Endoscopic Sinus Surgeries
NCT06975072	PHASE4	RECRUITING	Effect of Magnesium on Neuromonitoring
NCT07173855	PHASE4	RECRUITING	Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
NCT07328893	PHASE4	RECRUITING	Effect of Single Dose Intravenous Magnesium Sulfate on Postoperative Analgesic Consumption in Patients Undergoing Laparoscopic Cholecystectomy
NCT00120588	PHASE4	COMPLETED	Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth
NCT00325299	PHASE4	COMPLETED	Magnesium After Alcohol Withdrawal Treatment
NCT00994981	PHASE4	COMPLETED	Magnesium Administration in Liver Transplantation and Reperfusion Injury
NCT01151683	PHASE4	COMPLETED	Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients
NCT01342510	PHASE4	COMPLETED	Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol
NCT01408979	PHASE4	COMPLETED	Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia
NCT01756209	PHASE4	COMPLETED	Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood
NCT01894867	PHASE4	UNKNOWN	Magnesium in Liver Cirrhosis
NCT02184273	PHASE4	COMPLETED	Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children Undergoing Minor Surgery
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02481518	PHASE4	COMPLETED	Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity
NCT02508857	PHASE4	COMPLETED	Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02989272	PHASE4	UNKNOWN	Effect of Pre-treatment With Magnesium Sulfate on the Duration of Deep Neuromuscular Blockade With Rocuronium
NCT03322878	PHASE4	UNKNOWN	Magnesium Sulfate as an Adjuvant to Caudal Bupivacaine in Lower Abdominal Surgeries in Paediatrics.
NCT03393572	PHASE4	COMPLETED	Intraperitoneal Bupivacaine With Magnesium or Nalbuphine for Postoperative Pain Control in Laparoscopic Hysterectomy
NCT04111848	PHASE4	COMPLETED	Magnesium and Ketamine in Postoperative Analgesia
NCT04249804	PHASE4	COMPLETED	the Use of Magnesium Sulfate for Prevention of Postspinal Shivering
NCT04464005	PHASE4	UNKNOWN	Comparison Between Pads With Cold Solution of Magnesium Sulfate or Cold Water Postpartum Perineal Pain and Healing
NCT04651556	PHASE4	COMPLETED	Intraperitoneal Magnesium Sulphate and Bupivacaine Versus Intravenous Analgesia in Laparoscopic Surgeries in Pediatrics
NCT04776369	PHASE4	UNKNOWN	Effect of Lidocaine Versus Magnesium on Postoperative Pain in Spine Surgery
NCT04814381	PHASE4	COMPLETED	Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)
NCT05005494	PHASE4	UNKNOWN	Hypnotic and Anti-nociceptive Components of Magnesium
NCT05149820	PHASE4	UNKNOWN	Point of Care RandOmisation Systems for Performing Embedded Comparative Effectiveness Trials Of Routine Treatments
NCT05565235	PHASE4	UNKNOWN	Comparing Efficacy of Different Drugs Combinations for Serratus Anterior Block for Thoracotomy
NCT06743919	PHASE4	COMPLETED	Adding Magnesium Sulfate or Dexmedetomidine to Bupivacaine in Oblique Subcostal Tap Block for Laparoscopic Cholecystectomy: A Randomized Double -Blind Controlled Study
NCT06376916	PHASE3	RECRUITING	Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
NCT06721247	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Oral Intake of Mg in Controlled Asthmatic Patients
NCT06779461	PHASE3	NOT_YET_RECRUITING	A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
NCT06904287	PHASE3	RECRUITING	Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
NCT07147972	PHASE3	NOT_YET_RECRUITING	Comparative Study of Nutraceuticals vs. Conventional Prophylactic Therapy in the Management of Migraine
NCT07149649	PHASE2/PHASE3	NOT_YET_RECRUITING	Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00000610	PHASE3	COMPLETED	Magnesium in Coronaries (MAGIC)
NCT00040235	PHASE3	COMPLETED	Magnesium Effects in Apheresis
NCT00124150	PHASE3	COMPLETED	Intravenous Magnesium Sulfate in Aneurysmal Subarachnoid Haemorrhage (IMASH)
NCT00142233	PHASE3	COMPLETED	EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis
NCT00250965	PHASE3	TERMINATED	MPAACS: Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery
NCT00641784	PHASE3	TERMINATED	Tocolytics Trial: Intravenous (IV) Magnesium Versus Oral Nifedpine in Fetal Fibronectin (FFN) Postive Population
NCT00704990	PHASE2/PHASE3	COMPLETED	Combination Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT00965874	PHASE3	COMPLETED	Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation
NCT01087658	PHASE3	COMPLETED	Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity
NCT01132638	PHASE3	COMPLETED	Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
NCT01273883	PHASE3	COMPLETED	A Trial of Magnesium Dependent Tinnitus
NCT01336530	PHASE3	TERMINATED	Tepilta® Versus Oxetacaine, Antacids and Placebo
NCT02218424	PHASE2/PHASE3	COMPLETED	Magnesium vs Placebo for Tonsillectomy
NCT02446652	PHASE3	WITHDRAWN	Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
NCT02728037	PHASE3	TERMINATED	Magnesium-Based Trigger Point Injections for Relief of Chronic Myofascial Pelvic Pain
NCT03033823	PHASE3	COMPLETED	MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)
NCT03237819	PHASE3	UNKNOWN	Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care
NCT03558516	PHASE3	COMPLETED	Magnesium and Intraoperative Blood Loss in Meningioma Surgery
NCT04636411	PHASE3	COMPLETED	Effects of Oral Magnesium Supplementation on Patients With Type 2 Diabetes
NCT04645719	PHASE3	UNKNOWN	Dose of Magnesium Sulfate Infusion in Obese
NCT05287191	PHASE3	UNKNOWN	MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care
NCT05624151	PHASE3	COMPLETED	Dexmedetomidine Versus Magnesium Sulphate Added to Bupivacaine in Infraorbital Nerve Block for Perioperative Analgesia in Paediatric Patients for Cleft Lip Surgery
NCT05674565	PHASE2/PHASE3	UNKNOWN	Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries
NCT05825209	PHASE3	COMPLETED	Effectiveness of Food-grown Magnesium on Sleep Quality/Quantity
NCT06520475	PHASE3	COMPLETED	Efficacy of Bupivacaine-magnesium Combination Versus Bupivacaine Alone in Genicular Nerve Block
NCT05806996	PHASE2	RECRUITING	A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures
NCT06260072	PHASE2	RECRUITING	Magnesium and Riboflavin Treatment for Post-Concussion Headache
NCT07528612	PHASE2	NOT_YET_RECRUITING	MAG-PAIN - MAGnesium for Postoperative Analgesia In the Newly Delivered
NCT00029510	PHASE2	COMPLETED	Magnesium and Asthma - Clinical Trials
NCT00041392	PHASE2	COMPLETED	Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery
NCT00276146	PHASE2	WITHDRAWN	Dipyridamole/Magnesium To Improve Sickle Cell Hydration
NCT00323583	PHASE2	UNKNOWN	Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
NCT00500864	PHASE1/PHASE2	COMPLETED	Magnesium Loading in Chronic Obstructive Pulmonary Disease
NCT01074918	PHASE1/PHASE2	WITHDRAWN	Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients
NCT01148888	PHASE2	COMPLETED	The Effect of Magnesium Sulfate on Motor and Somatosensory Evoked Potentials in Children Undergoing Scoliosis Surgery
NCT01429415	PHASE2	COMPLETED	Magnesium Nebulization Utilization in Management of Pediatric Asthma
NCT01571908	PHASE2	COMPLETED	Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study
NCT02496676	PHASE1/PHASE2	COMPLETED	Magnesium Supplementation in People With XMEN Syndrome
NCT02602483	PHASE1/PHASE2	COMPLETED	Exploratory Study To Assess the Efficacy and Safety of a Triple Combination for Acute Pain Treatment in Patients With Temporomandibular Joint Disorders (TMJD).
NCT02709031	PHASE1/PHASE2	UNKNOWN	Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium
NCT02837328	PHASE2	COMPLETED	Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias
NCT03082625	PHASE2	UNKNOWN	Topical Magnesium and Muscle Cramps in Dialysis Patients.
NCT03223519	PHASE2	COMPLETED	COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS)
NCT03963479	PHASE2	UNKNOWN	Vitamin B6 and Magnesium- A Clinical Trial on ASD Patients
NCT04688203	PHASE1/PHASE2	COMPLETED	Effects Magnesium Sulfate and Labetalol Infusion on Peripheral Perfusion and Pain in Nasal Surgeries
NCT05166811	PHASE2	COMPLETED	Timely Intravenous Magnesium for Asthma in Children
NCT05653401	PHASE2	COMPLETED	Treatment of Renal Colic in the Emergency Department: Comparison Between Magnesium Sulfate and Lidocaine.
NCT06077539	PHASE1/PHASE2	UNKNOWN	Dexmedetomidine Versus Ketamine Versus Magnesium Sulfate for the Prevention of Emergence Agitation Following Sevoflurane Induced Anesthesia in Cardiac Catheterization in Pediatrics
NCT07079514	PHASE1/PHASE2	COMPLETED	Effect of Magnesium Sulfate on Hemodynamics on Laparoscopic Cholecystectomy Patients
NCT00346658	PHASE1	COMPLETED	Magnesium Supplementation to Prevent Bone Loss
NCT01157052	PHASE1	UNKNOWN	Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients
NCT01935570	PHASE1	COMPLETED	Comparative Study of the Bioavailability of Magnesium Administrated by Two ChronoMag Smart Tablet® 50 mg Versus Three Mag2® Tablets 100mg.
NCT02549521	PHASE1	COMPLETED	Mg Induced Changes From Day 0 to Day 28 on Serum and Urine Bone Metabolic Parameters in 70 y Old Females (no 50).
NCT04532775	PHASE1	UNKNOWN	Efficacy Of Magnesium In Radicular Pain When Added To Local Anesthetics And Steroids In Transforaminal Epidural Injection
NCT04929626	PHASE1	COMPLETED	Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus
NCT05032781	PHASE1	WITHDRAWN	Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention
NCT06516861	PHASE1	COMPLETED	Magnesium Sulphate and Lidocaine in Hemodynamic Changes and Cortisol Levels
NCT06137040	EARLY_PHASE1	RECRUITING	Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

90 molecules share ≥1 primary target. Top 90 by shared-target count:

Molecule	Source	Status	Shared targets
AMANTADINE	ChEMBL + PubChem	Phase 4 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
CHLORPROMAZINE	ChEMBL + PubChem	Phase 4 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
DEXTROMETHORPHAN	ChEMBL + PubChem	Phase 4 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
KETAMINE	ChEMBL + PubChem	Phase 4 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
LEVORPHANOL	ChEMBL + PubChem	Phase 4 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
MEMANTINE	ChEMBL + PubChem	Phase 4 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
ORPHENADRINE	ChEMBL + PubChem	Phase 4 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
CYCLOSERINE	ChEMBL	Phase 4 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
PROCYCLIDINE	ChEMBL	Phase 4 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
GLUTAMIC ACID	ChEMBL + PubChem	Phase 3 (approved)	GRIN2A, GRIN2B, GRIN2C, GRIN2D
DALZANEMDOR	ChEMBL	Phase 3	GRIN2A, GRIN2B, GRIN2C, GRIN2D
ESMETHADONE	ChEMBL	Phase 3	GRIN2A, GRIN2B, GRIN2C, GRIN2D
ALPHAMETHADOL	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
BUDIPINE	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
DEXTRORPHAN	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
DIZOCILPINE	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
IFENPRODIL	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
LANICEMINE	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
LEVOMETHADONE	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
LICOSTINEL	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
PERZINFOTEL	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
PHENCYCLIDINE	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
RACEMETHORPHAN	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
RADIPRODIL	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
SELFOTEL	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
TEZAMPANEL	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
TRAXOPRODIL	ChEMBL	Phase 2	GRIN2A, GRIN2B, GRIN2C, GRIN2D
BETAMETHADOL	ChEMBL	Phase 2	GRIN2A, GRIN2C, GRIN2D
TACRINE	ChEMBL	Phase 4 (approved)	GRIN2A, GRIN2B
LATREPIRDINE	ChEMBL	Phase 3	GRIN2A, GRIN2B
TETRAHYDROCANNABIVARIN	ChEMBL	Phase 2	TRPV5, TRPV6
ZELQUISTINEL	ChEMBL	Phase 2	GRIN2B, GRIN2C
Nimodipine	PubChem	Approved	GRIN2C, GRIN2D
Oxolinic Acid	PubChem	Approved	RYR2, RYR3
Propafenone	PubChem	Approved	HCN2, KCNJ2
Rosiglitazone	PubChem	Approved	TRPC5, TRPM3
Zuranolone	PubChem	Approved	HCN2, KCNJ2
CINACALCET	ChEMBL + PubChem	Phase 4 (approved)	CASR
ECONAZOLE	ChEMBL + PubChem	Phase 4 (approved)	TRPV6
ESKETAMINE	ChEMBL + PubChem	Phase 4 (approved)	GRIN2A
TOFACITINIB	ChEMBL + PubChem	Phase 4 (approved)	TRPM6
HALOPERIDOL	ChEMBL	Phase 4 (approved)	GRIN2B
PENTAMIDINE	ChEMBL	Phase 4 (approved)	GRIN2A
QUERCETIN	ChEMBL + PubChem	Phase 3 (approved)	TRPC5
ENCALERET	ChEMBL	Phase 3	CASR
EVOCALCET	ChEMBL	Phase 3	CASR
ALADORIAN	ChEMBL	Phase 2	RYR2
DEXOXADROL	ChEMBL	Phase 2	GRIN2A
DIMEMORFAN	ChEMBL	Phase 2	GRIN2A
ELIPRODIL	ChEMBL	Phase 2	GRIN2B
ETOXADROL	ChEMBL	Phase 2	GRIN2A
EVT-101 FREE BASE	ChEMBL	Phase 2	GRIN2B
FENDILINE	ChEMBL	Phase 2	CASR
ONFASPRODIL	ChEMBL	Phase 2	GRIN2B
RONACALERET	ChEMBL	Phase 2	CASR
SB-423562	ChEMBL	Phase 2	CASR
TECALCET	ChEMBL	Phase 2	CASR
TG100-115	ChEMBL	Phase 2	TRPM6
ZERENCOTREP	ChEMBL	Phase 2	TRPC5
Afatinib	PubChem	Approved	TRPM6
Axitinib	PubChem	Approved	TRPM6
Belzutifan	PubChem	Approved	KCNJ2
Boric Acid	PubChem	Approved	TRPV6
Bosutinib	PubChem	Approved	TRPM6
Caffeine	PubChem	Approved	RYR2
Capsaicin	PubChem	Approved	TRPV6
Crizotinib	PubChem	Approved	TRPM6
Dantrolene	PubChem	Approved	RYR2
Diphenhydramine	PubChem	Approved	TRPV6
Erlotinib	PubChem	Approved	TRPM6
Fedratinib	PubChem	Approved	TRPM6
Gefitinib	PubChem	Approved	TRPM6
Genistein	PubChem	Approved	TRPC5
Imatinib	PubChem	Approved	TRPM6
Ivabradine	PubChem	Approved	HCN1
Lapatinib	PubChem	Approved	TRPM6
Mefenamic Acid	PubChem	Approved	TRPM3
Midostaurin	PubChem	Approved	TRPM6
Neratinib	PubChem	Approved	TRPM6
Nilotinib	PubChem	Approved	TRPM6
Pazopanib	PubChem	Approved	TRPM6
Pioglitazone	PubChem	Approved	TRPM3
Progesterone	PubChem	Approved	TRPC5
Quizartinib	PubChem	Approved	TRPM6
Ruxolitinib	PubChem	Approved	TRPM6
Selumetinib	PubChem	Approved	TRPM6
Sorafenib	PubChem	Approved	TRPM6
Sunitinib	PubChem	Approved	TRPM6
tryptophan	PubChem	Approved	CASR
Vandetanib	PubChem	Approved	TRPM6